{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-053102","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.470962+00:00","generated_at":"2026-05-15T00:47:58.832545+00:00","sec_items":["2.02","5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TELA Bio reports preliminary Q1 revenue of $19.0M; Chairman and three directors to resign, new directors appointed","bullets":["Preliminary Q1 2026 revenue approximately $19.0M; unaudited and subject to change after close.","Chairman Doug Evans and directors Kurt Azarbarzin, Vince Burgess, Federica O'Brien to resign after 2026 annual meeting.","Board nominates Joseph Capper (CEO of MiMedx) for election as Class I director and future Chairman.","Board appoints Guido Neels, Guy Nohra, Paul Thomas as new directors effective after 2026 annual meeting.","Incoming directors and Capper to receive initial equity awards: options for 17,550 shares and RSUs for 11,925 shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-053102","json":"https://secwatch.observer/filing/0001104659-26-053102.json","markdown":"https://secwatch.observer/filing/0001104659-26-053102.md","text":"https://secwatch.observer/filing/0001104659-26-053102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/tm2612982d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:47:58.832545+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d5502e35788f4ddb913ba0ba4f03184de77eff7d","claim":"TELA Bio, Inc. reported quarter ended March 31, 2026 results: revenue approximately $19.0 million.","evidence_excerpt":"On April 29, 2026, TELA Bio, Inc. (the \" Company \") issued a press release announcing its preliminary unaudited revenue for the quarter ended March 31, 2026 of approximately $19.0 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2026"},{"label":"Revenue","value":"approximately $19.0 million"},{"label":"Result","value":"preliminary results"}]},{"claim_id":"1f407b9085","claim":"Kurt Azarbarzin resigned as Director at TELA Bio, Inc..","evidence_excerpt":"In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board...","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}]},{"claim_id":"3e0ffbe95d","claim":"Vince Burgess resigned as Director at TELA Bio, Inc..","evidence_excerpt":"In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board...","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}]},{"claim_id":"405a8c4eab","claim":"Guy Nohra was appointed as Director at TELA Bio, Inc..","evidence_excerpt":"On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director, with a term expiring at the 2027 Annual Meeting of the Company, and Guy Nohra and Paul Thomas as Class III directors...","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}]},{"claim_id":"6a3ba6b3d9","claim":"Federica O'Brien resigned as Director at TELA Bio, Inc..","evidence_excerpt":"In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board...","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}]},{"claim_id":"904d72b470","claim":"Paul Thomas was appointed as Director at TELA Bio, Inc..","evidence_excerpt":"On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director, with a term expiring at the 2027 Annual Meeting of the Company, and Guy Nohra and Paul Thomas as Class III directors...","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}]},{"claim_id":"9ecb9807db","claim":"Guido Neels was appointed as Director at TELA Bio, Inc..","evidence_excerpt":"On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director...","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}]},{"claim_id":"df25f191fa","claim":"Doug Evans resigned as Chairman of the Board at TELA Bio, Inc..","evidence_excerpt":"On April 29, 2026, Doug Evans, Chairman of the Board of Directors (the “ Board ”) of the Company, notified the Company and the Board that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “ 2026 Annual Meeting ”) and will retire from the Board...","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman of the Board"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}